1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Deals, April 2015

 
• By Deanna Kamienski, Beth Allan, Amanda Micklus, Maureen Riordan, and Steven Muntner

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.

Population Genetics, Case Western ally in diagnostics aimed at HIV drug resistance

Population Genetics Technologies Ltd. is teaming up with Case Western Reserve University to develop diagnostics for determining HIV...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 
• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 
• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

More from Business

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.